T/CSBME 079-2024 Active Group standards

T/CSBME 079-2024 The quality acceptance requirements for the clinical use of positron emission tomography/computed tomography (PET/CT) for lung cancer are as follows: The image quality of PET/CT for lung cancer should meet the following standards: - Clear image structure, without artifacts or noise - Sufficient contrast between normal and abnormal tissues, and good visualization of pathological changes - Good lesion detection sensitivity and specificity - Good inter-operator reproducibility and inter-scanner reproducibility The quality of the positron emission tomography (PET) imaging agent

Publish Date: 2024-02-26 Implement Date: 2024-05-01 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 54.00

Out of stock

Basic Information

Standard Code: T/CSBME 079-2024

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: Medical isotopes

ICS Name: Drugs

Publish Date: 2024-02-26

Implement Date: 2024-05-01

Pages: 32 pages

Scope

This document stipulates the quality acceptance requirements for the clinical use of PET/CT positron-emitting drugs in lung cancer diagnosis. This document applies to clinical medical institutions that conduct quality acceptance of PET/CT positron-emitting drugs purchased or compliantly self-manufactured before lung cancer PET/CT diagnosis. This document does not mandate that all clinical medical institutions implement the acceptance process before lung cancer PET/CT diagnosis, but if there are suspicions that the quality of the positron-emitting drugs may affect the accuracy of the diagnosis during the diagnosis process, it is recommended to refer to this document to conduct drug quality assessments and acceptance of the purchased or compliantly self-manufactured PET/CT positron-emitting drugs.